

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
18 January 2001 (18.01.2001)

PCT

(10) International Publication Number  
**WO 01/03696 A1**

- (51) International Patent Classification<sup>7</sup>: **A61K 31/44**, 31/505, 45/06, 31/66
- (74) Agent: **WAKERLEY, Helen, Rachael**; Reddie & Grose, 16 Theobalds Road, London WC1X 8PL (GB).
- (21) International Application Number: PCT/GB00/02681
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (22) International Filing Date: 11 July 2000 (11.07.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
9916536.7 14 July 1999 (14.07.1999) GB
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- (71) Applicant (*for all designated States except US*): **SCARISTA LIMITED** [GB/GB]; Kings Park House, Laurelhill Business Park, Polwaise Road, Stirling FK7 9JQ (GB).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): **HORROBIN, David, Frederick** [GB/GB]; Kings Park House, Laurelhill Business Park, Polwaise Road, Stirling FK7 9JQ (GB). **GOUAILE, Christina** [SE/SE]; Edvin Berlings gata 32, S-252 50 Heisingborg (SE).
- Published:**
- With international search report.
  - Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: PHARMACEUTICAL AND NUTRITIONAL COMPOSITIONS CONTAINING ESSENTIAL FATTY ACIDS AND HOMOCYSTEINE-LOWERING AGENTS

(57) Abstract: The combined application of at least one essential fatty acid of the n-6 or n-3 series, optionally together with further essential fatty acid(s) of the n-6 or n-3 series, together with one or more homocysteine lowering agent. The homocysteine lowering agent is selected from vitamin B12, folic acid, a compound related to folic acid with similar biological activity and vitamin B6.

WO 01/03696 A1

PHARMACEUTICAL AND NUTRITIONAL COMPOSITIONS CONTAINING ESSENTIAL FATTY ACIDS  
AND HOMOCYSTEINE-LOWERING AGENTS

In the past ten years evidence has accumulated which indicates that elevated blood and tissue levels of homocysteine indicate an increased risk of all forms of cardiovascular disease (including coronary heart disease, venous and arterial thrombosis and peripheral vascular disease) (M den Heijer et al, Arterioscler Thromb Vasc Biol 18: 356-361, 1998: M den Heijer et al Thromb Haemostas 80: 874-877, 1998: LM Taylor et al, J Vasc Surgery 29: 8-21, 1999: NJ Wald et al, Arch Intern Med 158: 862-867, 1998: H Refsum et al, Ann Rev Med 49: 31-62, 1998), of cerebrovascular disease and stroke (J-H Yoo et al, Stroke 29: 2478-2483, 1998: CDA Stehouwer et al, Arterioscler Thromb Vasc Biol 18: 1895-1901) of diabetes, pre-diabetes (insulin resistance or syndrome X) and its various complications including vascular disease, kidney disease, nerve damage and eye damage (S Neugebauer et al, Lancet 352: 454, 1998: AK Aarsand et al, J Internal Med 244: 169-174, 1998: EJ Giltay et al, Atherosclerosis 139: 197-198, 1998: E Okada et al, Diabetes Care 22: 484-490, 1999), of a range of psychiatric disorders including depression and schizophrenia (E Susser et al, Biol Psychiatry 44: 141-143, 1998: T Arinami et al, Am J Med Genetics 74: 526-528, 1997: C Gomes-Trolin et al, J Neural Trans, 105: 1293-1305, 1998: B Regland et al, J Neural Transm 98: 143-152, 1994: JE Albert et al, Nutrition Rev 55: 145-149, 1997: T Bottiglieri, Nutrition Rev 54: 382-390, 1996), of neurological disorders including Alzheimer's disease and other dementias (E Jensen et al, Arch Gerontol Geriatr 26: 215-226, 1998: R Clarke et al,

- 2 -

Arch Neurol 55: 1449-1455, 1998: M Lehmann et al, Dementia 10: 12-20, 1999), multiple sclerosis (STFM Frequin et al, J Neurol 240: 305-308, 1993: GA Qureshi et al, Biogenic Amines 12: 353-376, 1996) and  
5 Parkinson's disease, of kidney disorders and kidney failure (T Tamura et al, Am J Kidney Dis 32: 475-481, 1998: A Vychytil et al, Kidney Int 53: 1775-1782, 1998) of inflammatory disorders, including inflammatory bowel diseases and arthritis (SL Morgan et al, J Rheumatol  
10 25: 441-446, 1998: M Cattaneo et al, Netherl J Med 52: S1-61, 1998), of ear and eye disorders including age-related macular degeneration, age-related hearing loss and tinnitus (DK Houston et al, Am J Clin Nutr 69: 564-71, 1999), of cancers (DG Weir et al, Am J Clin Nutr  
15 68: 763-4, 1998: E Giovannucci et al, Ann Intern Med 129: 517-524, 1998) and of all-cause mortality (EK Hoogeveen et al, Netherlands J Med 52: S1-61, 1998). Homocysteine levels may also be elevated during obesity and particularly during its treatment (BF Henning et al, Res Exp Med 198: 37-42, 1998). Homocysteine-  
20 lowering nutrients may also be of value in the treatment of pain (J Leuschner, Arzneim-Forsch 42: 114-115, 1992) and during pregnancy for the prevention of congenital disorders such as spina bifida and of pregnancy problems such as pre-eclampsia or fetal growth restriction (M Leeda et al, Am J Obstet Gynecol  
25 179: 135-139, 1998). The mechanism of these widespread associations between elevated homocysteine and disease remains unknown but is likely to be something which operates at a fundamental biochemical level in many  
30 different tissues. One strong candidate is excessive oxidation promoted by homocysteine and its metabolites leading to changes in the functions of proteins and lipids (PB Young et al, Atherosclerosis 129: 67-71,

- 3 -

1997). The endothelium may be particularly vulnerable and since the endothelium is important in every tissue of the body this could provide a basis for the extraordinary range of pathology which is associated with elevated homocysteine (JC Chambers et al. Circulation 99: 1156-1160, 1999).

The main determinants of elevated homocysteine levels are deficits of folic acid and of vitamin B12 and, to a lesser extent, of pyridoxine and related substances with vitamin B6 activity. Homocysteine is mainly metabolised by conversion to methionine, which can then be used to make S-adenosyl-methionine which is used as a methyl donor in many different essential reactions, including the regulation of DNA and RNA functions and the syntheses of phospholipids, neurotransmitters and complex carbohydrates. The conversion of homocysteine to methionine is catalysed by the enzyme methionine synthetase: methyl-cobalamin, one of the forms of vitamin B12, plays a critical role in this reaction. A required co-factor for the enzyme is folic acid in the form of methyl-tetrahydrofolate. In the course of the reaction, a methyl group is transferred from 5-methyltetrahydrofolate to homocysteine, so producing tetrahydrofolate and methionine. Adequate intake and absorption of both folic acid and vitamin B12 are therefore required to keep homocysteine levels low and to ensure proper methylation reactions.

A secondary route for the metabolism of homocysteine involves its conversion to cystathionine and then to cysteine in two separate reactions, both of which require vitamin B6 as a co-factor. Inadequate availability of pyridoxine or related molecules may

- 4 -

therefore make a contribution to elevated homocysteine levels.

Optimal control of homocysteine metabolism therefore  
5 requires optimal body levels of vitamins B12 and B6 and  
also of folic acid or methyltetrahydrofolate or any  
other related substance which can provide folate.  
Vitamin B6 must be provided at a dose of at least 2mg  
per day, and preferably 5mg to 200mg per day. Vitamin  
10 B12 is normally provided by injection but can be given  
by mouth, even in those who lack the gastric intrinsic  
factor required for efficient absorption from the gut.  
Daily oral doses of vitamin B12 of at least 200 µg, and  
preferably 500 to 10,000 µg are required to ensure  
15 adequate tissue levels in those such as the elderly in  
whom B12 absorption may not be fully normal. The  
vitamin B12 may be provided as cyanocobalamin or  
hydroxocobalamin or any other biologically active form  
of the vitamin. Hydroxocobalamin is the preferred form  
20 since it is relatively stable and does not act as a  
cyanide donor. Folic acid should be provided in a dose  
of at least 200 µg/day and preferably more than  
500µg/day. The best results in control of elevated  
homocysteine will be obtained by the appropriate oral  
25 administration of all three vitamins. Appropriate  
daily doses applicable to most people would be 1mg to  
5mg of B12, preferably as hydroxocobalamin, 0.5 to 5mg  
of folic acid, and 2mg to 20mg of pyridoxine.

30 Essential fatty acids are another class of essential  
nutrients, so-called because they cannot be made within  
the body but have to be provided in the diet. There  
are two types of EFAs, n-3 (or omega-3) and n-6 (or  
omega-6) which are not interchangeable. The main

- 5 -

parent EFA of the n-6 group is linoleic acid, while the main parent fatty acid of the n-3 group is alpha-linolenic acid (figure 1). Although linoleic and alpha-linolenic acids are the most important EFAs in the diet, it is their metabolites which play the most important roles in the body. Although the metabolites cannot be synthesised de novo, they can be made from the parent EFAs by the pathways shown in figure 1. Particularly important members of the EFA families in terms of biological effects are dihomogammalinolenic acid (DGLA), arachidonic acid (AA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).

Just as elevated levels of homocysteine have been associated with a remarkably wide range of illnesses, so low levels of essential fatty acids, and particularly low levels of the metabolites DGLA, AA, EPA and DHA, have also been associated with a wide and very similar range of illnesses. The illnesses in which reduced levels of these fatty acids have been found include cardiovascular diseases, cerebrovascular diseases, thrombotic diseases, psychiatric diseases such as schizophrenia, depression and bipolar disorder, inflammatory diseases such as various forms of arthritis, eczema, asthma and inflammatory bowel disease, diabetes and its complications, kidney disease, neurodegenerative diseases like Alzheimer's disease and other dementias and Parkinson's disease, kidney diseases, many forms of cancer, and disorders of the reproductive system including male and female infertility and disorders of the breast and prostate (DF Horrobin, ed, Omega-6 Essential Fatty Acids: Pathophysiology and Roles in Clinical Medicine, Wiley-Liss, New York, 1990: DF Horrobin and CN Bennett,

- 6 -

Prostaglandins Leukotr Essential Fatty Acids, 60: in press, 1999: A Leaf et al, World Rev Nutr Diet 83: 24-37, 1998: DF Horrobin, Prostaglandins Leukotr Essential Fatty Acids, 53: 385-396, 1995).

5

Many studies have been performed in which EFAs have been used in attempts to treat diseases, including cardiovascular and cerebrovascular disorders, psychiatric and neurological disorders, renal disorders, inflammatory disorders of the skin, joints, respiratory and gastrointestinal systems, cancers and many other conditions. The EFAs which have been used have been particularly gamma-linolenic acid (GLA), DGLA, AA, EPA, and DHA, but also alpha-linolenic acid, linoleic acid and stearidonic acid. On the whole the results have shown beneficial effects but, equally, the effects have often been less than those hoped for by the authors.

20 Studies have also reported the levels of EFAs and the levels of homocysteine in patients or subjects: for example, in patients with end-stage renal disease, there has been reported an inverse relationship between the levels of homocysteine and the levels of DGLA, AA, EPA and DHA. Lowering homocysteine by treatment with folic acid produced elevations of these four fatty acids which were significant in the cases of DGLA and AA, but not significant in the cases of EPA and DHA (S Hirose et al. Jap J Nephrol 1998; 40: 8-16). Similarly, in rats made folic acid deficient, homocysteine levels became elevated and at the same time plasma levels of AA, EPA and DHA fell, the last two significantly so (P Durand et al, Atherosclerosis 1996; 121: 231-243). In another study, human maternal

- 7 -

plasma homocysteine levels were related to fatty acid levels in the red cells of the babies. There was a strong inverse relationship between maternal homocysteine and baby DHA (H Bohles et al. Eur J Pediatrics 158: 243-246, 1999).

The present invention is based on the inventors' observation that there may be a close relationship between the elevation of homocysteine and the deficits of EFAs, especially of AA, EPA and DHA. EFAs, with their multiple double carbon-carbon bonds, are highly susceptible to oxidation. Homocysteine and its metabolites could be promoting EFA-oxidation to reduce EFA levels.

Administration of the EFAs used in attempts to treat diseases may be being countered by their ongoing oxidation as a result of elevated levels of homocysteine. Thus the changes in EFA levels and the therapeutic effects of the EFAs will be less than expected. Moreover, since some of the oxidised EFA metabolites can be toxic, the desirable effects may be counteracted by undesirable ones.

Equally, attempts to lower homocysteine by means of folic acid, vitamin B12 or vitamin B6, either alone or in combination have often had desirable effects, but sometimes those desirable effects have been less than expected. This can be explained if some of the toxicity of homocysteine is attributable to loss of EFAs. Correction of elevated homocysteine will prevent the ongoing damage to the EFAs. However, since the EFAs cannot be synthesised de novo by the body, controlling homocysteine will do nothing to increase



- 8 -

the supply of EFAs to help replace those which have been lost.

5 The following invention thus provides the combined application of one or more EFAs, together with one or more homocysteine lowering agents, for use in therapy of any disorder, but particularly of those disorders discussed earlier in this specification. It is preferred that the EFAs are administered in a  
10 formulation which has no significant amounts of other micro-nutrients; preferably the active ingredients of the formulation consist essentially wholly of the selected EFA(s) and the homocysteine lowering agent(s).

15 The homocysteine lowering agent(s) are preferably selected from Vitamin B12, folic acid, a compound related to folic acid and with similar biological activity and Vitamin B6. All four of these  
20 homocysteine-lowering agents can be administered together with the EFA, or any two or three of them. For example, it may not be appropriate to administer both folic acid and a compound related to folic acid. The folic acid could be administered with vitamin B12  
25 or vitamin B6 or both. The other option is to choose just one of the homocysteine-lowering agents.

30 The most preferred EFAs used in the formulations of the present inventions are eicosapentaenoic acid (EPA) and arachidonic acid (AA). The EPA can be in the form of pure tri-EPA triglyceride or, more preferably, the ethylester. For any of the EFAs selected, the EFA may be in the purified or partly purified form, though preferably the purified form.

- 9 -

The formulations of the present invention are set out in the attached claims.

5 The lowering of homocysteine will prevent ongoing damage to the EFAs, and so make the desirable results of EFA administration more likely. Equally, the provision of EFAs will help to replenish fatty acids lost through elevated homocysteine levels, and so make a desirable response to lowering homocysteine more  
10 likely.

EFAs and homocysteine lowering nutrients have been naturally coadministered in the form of human and artificial milks, eggs and of other nutrient complete  
15 foods. However, they have not previously been administered in pharmaceutical or nutritional supplement dose forms, nor in the doses likely to be required for therapeutic as opposed to nutritional effects. In particular, oral administration of vitamin  
20 B12 in relatively high doses has rarely been employed, neither natural or artificial milks, nor multivitamin mixes for oral or enteral administration, contain levels of vitamin B12 which are anywhere close to 200 µg/day. Similarly, these foods contain levels of folic  
25 acid and of vitamin B6 which are far below 100 µg/day for folic acid and 1.5mg per day vitamin B6.

For example, dried milk which is the complete food richest in these nutrients contains only 0.23mg vitamin  
30 B6, 2.0 µg vitamin B12 and 40 µg folic acid per 100g [The Composition of Foods, AA Paul and DAT Southgate, HMSO, London 1988]. 100g of dried milk products provides about 500 calories and so it would be impossible to consume more than about 500g/day of dried

- 10 -

milk. Even this large amount would only provide 1.15mg vitamin B6 and 10.0 µg vitamin B12.

5 The EFAs in the compositions and uses of the present invention may be in any form which leads to a rise in the level of the relevant EFA molecule in the plasma or in cell membranes. Appropriate forms include mono-, di- and triglycerides, phospholipids, esters of any form, including ethyl, propanediol or any other  
10 appropriate form of ester, amides, salts, including lithium, sodium and potassium salts, and any other compounds which, following oral, parenteral or topical administration lead to an increase in blood or tissue levels of the EFAs concerned. Particularly appropriate  
15 forms which are known to be highly compatible with administration to the human or animal body are triglycerides and ethyl esters, for example of GLA, DGLA, AA, EPA or DHA. The EFAs may be administered in doses of from 10mg to 100g per day, preferably 50mg to  
20 20g per day, and very preferably 100mg to 5g/day. The EFAs may be provided in the form of natural oils, partially or completely purified natural oils in which the other components have been removed, or chemically derivatised pure or partially purified lipid forms.  
25 The EFA component of the formulation must contain at least 5% of the relevant EFA or EFA derivative, preferably more than 15%, and very preferably more than 30%, 50%, 90% or 95%.

30 The homocysteine-lowering agents used in the compositions and uses of the present invention are selected from vitamin B12, folic acid or a related compound with similar biological activity and vitamin B6. The preferred form of vitamin B12 is

- 11 -

hydroxocobalamin, though cyanocobalamin or any other biologically active form of the vitamin may be used. If present, more than 10 µg/day vitamin B12 is required. The preferred dosage is at least 200 µg, preferably 500 - 10,000 µg, still preferably 1mg - 5mg per day. Folic acid may be used as it is or in the form of methyltetrahydrofolate or any other related substance which can provide folate. The preferred dosage is at least 200 µg, preferably more than 500 µg and still preferably 0.5 - 5 mg per day. Vitamin B6 may be used in the form of pyridoxine. If present, at least 1.5 mg/day vitamin B6 is required. The preferred dose is at least 2 mg, preferably 5 - 200 mg, still preferably 2 - 20 mg per day. Overall, it is preferred that at least 200 µg/day homocysteine lowering agent is required, whatever the identity of the said agent(s).

The EFAs and homocysteine-lowering nutrients may be mixed together in powders or liquids, may be administered together in tablets, hard or soft gelatin capsules, microcapsules or any other appropriate dosage form known to those skilled in the art. The EFAs and the homocysteine-lowering nutrients may also be given in separate dosage forms but provided together in a single pack with instructions for daily administration of both components. The formulations may comprise conventional diluent and/or excipients and flavouring agents may be added.

One of the problems of using EFAs either in nutrition or in therapy is that they are easily oxidised within the body to a wide range of products, some of which may be harmful. The body has a system of antioxidant devices to deal with this, but not every individual may

- 12 -

have adequate antioxidant defences. This is because several of the key antioxidants are essential nutrients which must be provided in the diet and not all diets are adequate. It is therefore advantageous to provide with the formulations one or more antioxidants. Antioxidants of particular value are vitamin E in any of its natural or artificial forms, coenzyme Q in any of its natural or artificial forms, alpha-lipoic acid in any of its natural or artificial forms and vitamin C in any of its natural or artificial forms. When the antioxidant component is required, it may include any one or any combination of these agents. If present, the dosage of antioxidant is preferably from 1 mg to 5000 mg per day.

#### BRIEF DESCRIPTION OF THE FIGURES

Fig 1. The n-3 and n-6 series of essential fatty acids

#### EXAMPLES

1. Hard or soft gelatin capsules containing 500mg of ethyl-eicosapentaenoate or of eicosapentaenoic acid triglyceride, together with 1mg of hydroxocobalamin, 1mg of folic acid and 2mg of pyridoxine, to be taken two to four times a day.

2. A formulation as in 1 but in which the eicosapentaenoate is first microencapsulated with any appropriate microencapsulating agent and then tabletted with the other ingredients.

- 13 -

3. A solution for oral administration in which 500mg of an eicosapentaenoate derivative, 1mg of folic acid, 1mg of hydroxocobalamin and 5mg of pyridoxine are present in 5ml with appropriate flavouring.

5

4. An emulsion for parenteral administration in which 500mg of the eicosapentaenoate derivative is emulsified in a total volume of 10ml, which includes in solution 1mg of hydroxocobalamin, 1mg of folic acid and 5mg of pyridoxine.

10

5-8. As examples 1 to 4 but in which the EFA is selected from arachidonic acid, gamma-linolenic acid, dihomogammalinolenic acid, stearidonic acid, eicosapentaenoic acid, docosapentaenoic acid, docosahexaenoic acid, linoleic acid or alpha-linolenic acid or their derivatives.

15

9-12. As examples 1 to 4, but in which two or three EFAs selected from the list in 1-8 are coadministered to give a total of 500mg of EFA per oral encapsulated or tabletted dosage form, per 5ml solution, or per 10ml parenteral emulsion.

20

13-24. As 1-12 but in which the only homocysteine-lowering component provided is vitamin B12.

25

25-36. As 1-12 but in which the only homocysteine-lowering component provided is folic acid.

30

37-48. As 1-12 but in which the only homocysteine-lowering component provided is vitamin B6.

- 14 -

49-96. As 1-48 in which one or more antioxidants selected from vitamin E, coenzyme Q, alpha-lipoic acid and vitamin C is added to the formulation. Vitamin E, coenzyme Q, alpha-lipoic acid and vitamin C may be used in doses of from 1mg to 5000mg per day,

5

- 15 -

CLAIMS

1. A pharmaceutical formulation comprising one or more EFAs selected from those shown in Fig. 1 together with one or more homocysteine-lowering agents, selected from Vitamin B12, folic acid, a compound related to folic acid with similar biological activity and vitamin B6, and a pharmaceutically acceptable excipient.
2. A nutritional formulation in the dosage form of a hard or soft gelatin capsule comprising one or more EFAs selected from those shown in Fig. 1 together with one or more homocysteine-lowering agents selected from Vitamin B12, folic acid, a compound related to folic acid with similar biological activity and vitamin B6.
3. A pharmaceutical or nutritional formulation comprising one or more EFAs selected from those shown in Fig. 1 together with one or more homocysteine-lowering agents selected from Vitamin B12, folic acid, a compound related to folic acid with similar biological activity and vitamin B6, the formulation comprising 200 µg or more of the one or more homocysteine-lowering agents.
4. A formulation according to any preceding claim in which the EFA is eicosapentaenoic acid (EPA).
5. A formulation according to any of claims 1-3 in which the EFA is eicosapentaenoic acid (EPA) in the form of the ethyl ester or of the pure tri-EPA triglyceride.
6. A formulation according to any of claims 1-3 in which the EFA is arachidonic acid.



- 16 -

7. A formulation according to any of claims 1-3 in which the EFA is gammalinolenic acid or dihomogammalinolenic acid.

5 8. A formulation according to any of claims 1 to 3 in which the EFA is docosahexaenoic acid.

9. A formulation according to any preceding claim comprising two or more EFAs.

10

10. A formulation according to any preceding claim comprising at least 5% EFA, preferably more than 15% EFA, very preferably more than 30%, more then 50%, more than 90% or more than 95% EFA.

15

11. A formulation according to any preceding claim comprising vitamin B12, preferably in the form of hydroxocobalamin, as the only homocysteine-lowering agent.

20

12. A formulation according to any of claims 1 - 10 comprising folic acid or a related compound with similar biological activity as the only homocysteine-lowering agent.

25

13. A formulation according to any preceding claim in a form suitable for oral administration.

30

14. A formulation according to any preceding claim further comprising one or more antioxidants selected from natural, synthetic or semi-synthetic forms of vitamin E, coenzyme Q, alpha-lipoic acid and vitamin C.

- 17 -

15. A formulation according to any of claims 1 and 3 -  
14 for use in therapy or prevention or for the  
manufacture of a medicament for use in therapy or  
prevention of one or more of the following conditions:

- 5           a. Any illness;
- b. Any cardiovascular or cerebrovascular  
              disorder, including any form of  
              atherosclerosis of the coronary, cerebral or  
10           peripheral blood vessels, any form of heart  
              disease, any form of cerebrovascular disease  
              or stroke, any form of peripheral vascular  
              disease and any form of thrombosis;
- c. Any form of diabetes or pre-diabetes  
              (syndrome X) and any of the macro- or  
15           microvascular complications of diabetes  
              including cardiovascular disease,  
              retinopathy, nephropathy or neuropathy;
- d. Any form of psychiatric disorder including  
              schizophrenia, schizotypal disorder and other  
20           schizophreniform disorders, bipolar disorder  
              (mania, or manic depression), depression of  
              any form, and panic or anxiety disorders,  
              sleep disorders and social phobias;
- e. Any form of neurological or neurodegenerative  
25           disorder including Alzheimer's disease and  
              other forms of dementia, Parkinson's disease,  
              multiple sclerosis, Huntington's disease and  
              any form of chronic pain;
- f. Any form of kidney disorder;
- 30           g. Any form of inflammatory or immunological  
              disorder of the gastrointestinal tract, the  
              respiratory system, the skin and mucous  
              membranes, or the joints or any other  
              tissues;

- 18 -

- 5
- h. Any form of eye or hearing disorder including age-related macular degeneration, age-related deafness, or tinnitus;
  - I. Any form of obesity, and particularly any method of treatment of obesity;
  - j. Any form of cancer.

1/1

Fig. 1

# ESSENTIAL FATTY ACID (EFA) METABOLISM

n-6 series		n-3 series	
18:2n-6	LINOLEIC	ALPHA LINOLENIC	18:3n-3
	Delta-6-desaturation		
18:3n-6	GAMMA-LINOLENIC	STEARIDONIC	18:4n-3
	Elongation		
20:3n-6	DIHOMO GAMMALINOLENIC	EICOSA TETRAENOIC (n-3)	20:4n-3
	Delta-5-desaturation		
20:4n-6	ARACHIDONIC	EICOSAPENTAENOIC	20:5n-3
	Elongation		
22:4n-6	ADRENIC	DOCOSAPENT AENOIC (n-3)	22:5n-3
	Delta-4-desaturation		
22:5n-6	DOCOSAPENTAENOIC (n-6)	DOCOSAHEXAENOIC	22:6n-3

# INTERNATIONAL SEARCH REPORT

International Application No.

PCT/GB 00/02681

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/44 A61K31/505 A61K45/06 A61K31/66

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, PAJ, WPI Data, BIOSIS, CHEM ABS Data, EMBASE

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 99 03482 A (E.M.PIPER) 28 January 1999 (1999-01-28) claims 1,2,5 page 2, line 21-27 page 3, line 4-8	1-3,7, 12-15
X	EP 0 305 097 A (EFAMOL HOLDINGS PLC) 1 March 1989 (1989-03-01)  claims 1,5,6,10-12 page 3, line 1-25 page 3, line 52-57 page 4, line 34-37 examples 14-19	1,2,4, 6-9,11, 13-15



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

### \* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

2 November 2000

Date of mailing of the international search report

15/11/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Peeters, J

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/GB 00/02681

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>O.HAGLUND E.A.: "Effects of fish oil supplemented with pyridoxine and folic acid on homocysteine, atherogenic index, fibrinogen and plasminogen activator inhibitor-1 in man"</p> <p>NUTRITION RESEARCH, vol. 13, no. 12, 1993, pages 1351-1365, XP000960304 page 1351 page 1354 page 1357</p> <p style="text-align: center;">-----</p>	<p>1,3-5, 8-10, 12-15</p>

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 00/02681

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9903482 A	28-01-1999	AU 8450098 A	10-02-1999
		GB 2342045 A	05-04-2000
EP 305097 A	01-03-1989	AT 65182 T	15-08-1991
		AT 96327 T	15-11-1993
		AU 618730 B	09-01-1992
		AU 1536188 A	27-10-1988
		AU 2147988 A	02-03-1989
		CA 1306944 A	01-09-1992
		CA 1332358 A	11-10-1994
		DE 3863678 D	22-08-1991
		DE 3885212 D	02-12-1993
		DE 3885212 T	07-04-1994
		DK 225588 A	28-10-1988
		DK 469488 A	26-02-1989
		EP 0289204 A	02-11-1988
		EP 0432700 A	19-06-1991
		ES 2040847 T	16-07-1996
		GR 3002426 T	30-12-1992
		HK 127793 A	26-11-1993
		IE 60568 B	27-07-1994
		IE 61750 B	30-11-1994
		JP 1013021 A	17-01-1989
		JP 2699083 B	19-01-1998
		JP 1083021 A	28-03-1989
		KR 9613433 B	05-10-1996
		KR 9700043 B	04-01-1997
		NZ 224380 A	25-06-1991
		NZ 225909 A	28-04-1992
		SG 113593 G	21-01-1994
		US 5252333 A	12-10-1993
		US 5422115 A	06-06-1995
		ZA 8806322 A	30-05-1989

**THIS PAGE BLANK (USPTO)**